The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Subscribe To Our Newsletter & Stay Updated
